Compounded vs brand-name GLP-1, explained

If you've shopped for a GLP-1 online, you've run into two very different kinds of product at very different prices: brand-name Wegovy or Zepbound on one side, and compounded semaglutide or tirzepatide on the other. They share an active ingredient, but they are not the same thing in the eyes of the FDA, your wallet, or your pharmacist. Here's the plain-English version of the difference.

What 'brand-name' means

Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved products. That means the specific formulation, dose, and manufacturing were reviewed and cleared by the FDA, and each ships with an official label describing approved uses, dosing, warnings, and contraindications¹². Both are approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who meet the labeled BMI criteria¹². The upside is a known, standardized product; the downsides are price and, historically, availability.

What 'compounded' means

Compounded semaglutide and tirzepatide are made by licensed compounding pharmacies — 503A pharmacies that fill patient-specific prescriptions, or larger 503B outsourcing facilities. Compounded drugs are not FDA-approved as products; the agency does not review each compounded formulation for safety and efficacy the way it does an approved drug³. Compounding has a real, legal place in medicine, but it puts more weight on the quality of the specific pharmacy involved — which is why sourcing matters so much in this category.

Why compounding surged — and why that's shifting

For much of the recent GLP-1 boom, brand-name supply couldn't keep up with demand, and both molecules spent long stretches on the FDA drug-shortage list⁴. During a shortage, compounders have more latitude to make copies of a drug in short supply. As the brand shortages resolved, the FDA moved to wind down that latitude — which is exactly why the compounded market is under more regulatory attention now than it was a year ago. We track the moving pieces in GLP-1 shortages and supply.

The price gap

The most obvious difference is cost. Brand-name products carry high list prices and are often only affordable with insurance coverage; compounded versions are frequently a fraction of the out-of-pocket cost, which is why so many cash-pay telehealth desks lead with them. On the Dose Brief ranking, compounded monthly prices range widely by provider — figures reflect each provider's published pricing at last review (August 2026), not a medical claim. See the current compounded semaglutide price ranking for who's actually selling it and at what price this cycle. If a low price is the whole appeal, read why GLP-1 prices move first, because compounded pricing is where teaser rates and step-ups are most common.

Same warnings apply

Whichever route you take, the underlying molecule carries the same safety profile the FDA describes on the brand labels: a boxed warning about thyroid C-cell tumors seen in rodent studies, and a contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2¹². Compounding doesn't make those cautions go away. A good provider screens for them regardless of which product you're getting.

How to choose between them

There's no universal winner. Brand-name makes sense if you want an FDA-approved product, have insurance that helps, or simply prefer the standardized option. Compounded makes sense if you're paying cash and want a lower price — provided you vet the pharmacy carefully. If you go compounded, work through is compounded semaglutide legit? and our 5-minute provider checklist. Some desks offer both, which lets you keep your options open: RxSpan MD itemises Ozempic at $1,299, Wegovy at $1,349 and Zepbound at $1,069 cash-pay on the same storefront as its $249-a-month compounded semaglutide, so the size of the gap is visible in one place rather than assembled from two sites. If tirzepatide specifically is your molecule, our tirzepatide-focused price tracker breaks out compounded pricing and footprint by desk. A newer wrinkle to watch is the arrival of oral GLP-1 pills, which are exactly the kind of not-yet-approved product gray-market sellers tend to imitate first. This is background for a conversation with a clinician, not medical advice.

This piece sits in our evidence hub alongside every other sourced explainer we publish — the trials, the compounding rules, and the pricing mechanics, grouped by the question each one answers.